QPX-9003 is under clinical development by Qpex Biopharma and currently in Phase I for Pseudomonas aeruginosa Infections. According to GlobalData, Phase I drugs for Pseudomonas aeruginosa Infections have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how QPX-9003’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

QPX-9003 overview

QPX-9003 is under development for the treatment of multi-drug resistant acinetobacter baumannii, enterobacteriaceae and pseudomonas aeruginosa infections. The therapeutic drug candidate is administered through intravenous route. It is a lipopeptide analog, the new-generation polymyxin.

Qpex Biopharma overview

Qpex Biopharma is a biopharmaceutical company that discovers and develops therapies for infectious diseases. It is investigating ORAvance, an oral treatment beta-lactamase inhibitor targeting extended spectrum beta lactamase (ESBL) and carbapenem-resistant enterobacteriaceae (CRE) infections; OMNIvance drug against infections caused due to acinetobacter, pseudomonas, and enterobacteriaceae. The company is also developing QPX9003, a next gen synth polymyxin to treat multidrug-resistant (MDR) pseudomonas and acinetobacter infections. Qpex Biopharma is headquartered in San Diego, California, the US.

For a complete picture of QPX-9003’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.